Lancet发文:全文仅64字,中国学者在刊文指出研究缺陷

2020-06-17 网络 网络

近期,北京协和医学院邓晓明等人在国际顶级医学期刊Lancet在线发表题为“Pain relief during labour”的通讯文稿(Correspondence),该文章

近期,北京协和医学院邓晓明等人在国际顶级医学期刊Lancet在线发表题为“Pain relief during labour”的通讯文稿(Correspondence),该文章仅仅只有64字,指出了Matthew Wilson等人在Lancet发表的题为“Intravenous remifentanil patient-controlled analgesia versus intramuscular pethidine for pain relief in labour (RESPITE): an open-label, multicentre, randomised controlled trial”的文章存在缺陷,认为作者如果能解决这些缺陷,可以进一步提高其研究价值。

Matthew Wilson and colleagues found that remifentanil patient-controlled analgesia halved the proportion of epidural conversions compared with intramuscular pethidine. We believe there was a flaw in this research because the study lacked data on birth order, and primigravidae report more pain than multiparous women. We believe that addressing this issue could further increase the value of their study. We declare no competing interests.

全文的意思如下:

Matthew Wilson及其同事发现,与肌内注射哌替啶相比,瑞芬太尼患者自控镇痛使硬膜外转换的比例减半。我们认为这项研究存在缺陷,因为该研究缺乏关于出生顺序的数据,并且初产妇报告的疼痛比多产妇女更多。我们认为解决这个问题可以进一步提高他们的研究价值。我们宣布没有竞争利益。

梅斯医学小编:

如果发现原始文章有缺陷,可以写一个通讯稿,也可以发表哦!

原始出处:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30712-3/fulltext#%20
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31613-1/fulltext

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830696, encodeId=c43f18306963d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 21 22:25:13 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813731, encodeId=2833813e31ad, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:03:56 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602436, encodeId=590d602436f0, content=牛文, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jun 17 20:33:27 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033840, encodeId=925710338400e, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 17 11:25:13 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
    2020-07-21 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830696, encodeId=c43f18306963d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 21 22:25:13 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813731, encodeId=2833813e31ad, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:03:56 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602436, encodeId=590d602436f0, content=牛文, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jun 17 20:33:27 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033840, encodeId=925710338400e, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 17 11:25:13 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    👍

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1830696, encodeId=c43f18306963d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 21 22:25:13 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813731, encodeId=2833813e31ad, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:03:56 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602436, encodeId=590d602436f0, content=牛文, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jun 17 20:33:27 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033840, encodeId=925710338400e, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 17 11:25:13 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
    2020-06-17 lovetcm

    牛文

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1830696, encodeId=c43f18306963d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jul 21 22:25:13 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813731, encodeId=2833813e31ad, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 08:03:56 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602436, encodeId=590d602436f0, content=牛文, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jun 17 20:33:27 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033840, encodeId=925710338400e, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Jun 17 11:25:13 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
    2020-06-17 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

相关资讯

Lancet:瑞芬太尼自控镇痛用于产前阵痛

研究认为瑞芬太尼病人自控镇痛对于分娩阵痛的控制效果优于哌替啶,有望成为分娩镇痛的新一线方法

瑞芬太尼在老年患者快速序贯诱导中的有效性和安全性研究:一项三臂平行双盲随机对照试验

老年患者快速序贯诱导(RSI),使用瑞芬太尼(0.5-1.0μg/kg)可预防心动过速和高血压的发生。

瑞芬太尼在重症监护室镇痛镇静方案中的应用

提供有效的镇痛和充分的镇静是重症监护医学的普遍接受的目标。由于超短效的阿片类药物瑞芬太尼的快速、器官保护和代谢时间可预知等特性,使它对重症监护病房(ICU)中基于镇痛的镇静策略非常有用。

重症医学:瑞芬太尼:重症监护病房镇痛镇静应用的综述

瑞芬太尼是一种芬太尼的4-苯胺哌啶衍生物,是一种超短效μ-阿片受体激动剂,可用于重症监护病房(ICU)中的机械通气患者,提供镇痛和镇静作用。 应用瑞芬太尼行镇痛为基础的镇静,对ICU中的机械通气患者来说,是一种有用的选择。其独特的特性(例如非器官依赖代谢、缺乏堆积、快速失效)使其不同于其他阿片类药物。在ICU机械通气患者中,瑞芬太尼至少与对比的阿片类药物如芬太尼、吗啡和舒芬太尼一样有效,可提

瑞芬太尼在早产儿脐血中的降解研究

Lars Welzing 等作者论证了瑞芬太尼在早产儿中代谢速率的问题,现对作者的文章进行总结。

Anaesthesia:瑞芬太尼与右美托咪定用于术中镇痛的比较:系统回顾与meta分析

术中瑞芬太尼的使用与术后镇痛需求及阿片类药物使用量增加有关。右美托咪定具有可取代瑞芬太尼用于术中全身麻醉的特点,但现有文献报道的结果之间相互矛盾。我们进行这项meta分析,旨在探讨是否使用包括右美托咪定在内的全身麻醉会比使用包括瑞芬太尼在内的全身麻醉所引起的术后疼痛更少。